3 terminated. 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Terminated 3 |
Follow Morphological and Microscopic Findings: new trials by email Literature Review of Morphological and Microscopic Findings trials Research Report on Morphological and Microscopic Findings
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Topical ABI-1968 in Subjects With Precancerous Anal Lesions Resulting From Human Papillomavirus (HPV) Infection Topical ABI-1968 cream - HSIL, High-Grade Squamous Intraepithelial Lesions, Human Papilloma Virus Infection | Phase 1 | Terminated | Antiva Biosciences | 6 | 2018-12-17 | 2019-07-24 |
| Immunotherapy With E6 T Cell Receptor (TCR) T Cells for Vulvar High-Grade Squamous Intraepithelial Lesions Aldesleukin, E6 T Cell Receptor (TCR) - Human Papillomavirus, HPV-16 | Phase 1 | Terminated | National Cancer Institute (NCI) | 1 | 2018-01-09 | 2021-02-16 |
| Safety, Tolerability, and Immunogenicity of GTL001 Vaccine Adjuvanted With Imiquimod Cream in HPV 16- and/or HPV 18-Infected Women Aged 25 to 65 Years, With Normal Cytology, ASCUS, or LSIL GTL001+, Aldara - HPV 16- and/or HPV 18-Infected Women With Normal Cytology, ASCUS, or LSIL | Phase 1 | Terminated | Genticel | 13 | 2015-08-01 | 2016-12-02 |
Squamous Intraepithelial Lesions (2) · Anus Neoplasms (1) · Atypical Squamous Cells of the Cervix (1) · HIV Infections (1) · Papillomavirus Infections (1)
Pathological Conditions, Signs and Symptoms (3) · Genital Diseases (2) · Neoplasms (2) · Urogenital Diseases (2) · Anus Diseases (1) · Blood-Borne Infections (1) · Colorectal Neoplasms (1) · Communicable Diseases (1) · DNA Virus Infections (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Disease Attributes (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1)
Imiquimod (1) · Interleukin-2 (1) · aldesleukin (1)
Antiva Biosciences (1) · Genticel (1) · National Cancer Institute (NCI) (1)
United States (3) · Australia (1)